Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
Sponsor: Hoffmann-La Roche
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Official title: A Phase II, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants With Early-stage Parkinson's Disease
Key Details
Gender
All
Age Range
40 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
474
Start Date
2026-09-30
Completion Date
2032-04-15
Last Updated
2026-09-21
Healthy Volunteers
No
Conditions
Interventions
RO7568282
RO7568282 will be administered as per the schedule specified in the protocol.
Placebo
Placebo will be administered as per the schedule specified in the protocol.